

# Arix Bioscience PLC

07:40 26 Mar 2019

## Arix Bioscience's portfolio company Autolus announces positive safety data for AUTO3 ahead of inaugural R&D day

Arix Bioscience PLC's (LON:ARIX) portfolio company, Autolus Therapeutics, has announced positive updated safety and efficacy data for its AUTO3 leukaemia drug ahead of its inaugural R&D day in New York.

Updated data from the ongoing AMELIA Phase I/II study showed that all six patients treated at the highest dose achieved minimal residual disease (MRD) negative complete responses (CR).

**READ:** Arix invests US\$15m in sickle cell treatment developer

A patient who tests MRD negative has less than one cancer cell per million bone marrow cells, meaning the disease is all but gone.

Ongoing MRD negative CR remissions were noted in four of the six patients, with duration of up to 10 months as of February 2019, the date of latest data follow-up.

Nasdaq-listed Autolus added that AUTO3 continues to be generally well tolerated with none of the patients needing critical care for cytokine release syndrome - a condition that occurs with some forms of immunotherapy.

The Phase II portion of the study remains on track to begin in the second half of this year.

**R&D day later today**

Autolus made the announcement ahead of its inaugural R&D day in New York which is due to get underway later today.

Chairman and chief executive Christian Itin will be one of those giving a presentation, as will several other execs.

"We are pleased to be hosting our inaugural R&D day, providing a unique opportunity to present an in-depth overview of our differentiated technology, multiple programs, market opportunities and the significant pipeline progress we have achieved, to date," said Autolus boss Itin.


"We expect to report data on all of our active clinical programs at key medical conferences during 2019. Additionally, over the coming months, we expect to move two programs into registrational trials and to progress our next generation programs toward the clinic."

Shares in Arix, which has results out on Thursday, edged 1% higher to 145.5p in late-morning trading on Tuesday.

**Price:** £1.19

**Market Cap:** £160.63 m

### 1 Year Share Price Graph



September 2018 March 2019 September 2019

### Share Information

**Code:** ARIX

**Listing:** LSE

52 week	High	Low
	182	106

**Sector:** Medical technology & services

**Website:** arixbioscience.com

### Company Synopsis:

*Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients.*

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts

journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).